These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38029547)

  • 21. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
    Nakamura M; Aoyama T; Ishibashi K; Tsuji A; Takinishi Y; Shindo Y; Sakamoto J; Oba K; Mishima H
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):29-36. PubMed ID: 27878354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and prognostic value of the
    Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W
    Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
    Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
    Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.
    Okada S; Hata K; Kawai K; Yamamoto Y; Tanaka T; Nishikawa T; Sasaki K; Kaneko M; Emoto S; Murono K; Nozawa H
    Medicine (Baltimore); 2019 Mar; 98(12):e14781. PubMed ID: 30896620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
    Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
    Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
    Rabara D; Tran TH; Dharmaiah S; Stephens RM; McCormick F; Simanshu DK; Holderfield M
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22122-22131. PubMed ID: 31611389
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.
    Durojaye OA; Ejaz U; Uzoeto HO; Fadahunsi AA; Opabunmi AO; Ekpo DE; Sedzro DM; Idris MO
    Amino Acids; 2023 Dec; 55(12):1745-1764. PubMed ID: 37500789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of KRAS mutations in patients with colorectal cancer.
    Inoue Y; Saigusa S; Iwata T; Okugawa Y; Toiyama Y; Tanaka K; Uchida K; Mohri Y; Kusunoki M
    Oncol Rep; 2012 Nov; 28(5):1579-84. PubMed ID: 22922794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic KRAS suppresses store-operated Ca
    Pierro C; Zhang X; Kankeu C; Trebak M; Bootman MD; Roderick HL
    Cell Calcium; 2018 Jun; 72():70-80. PubMed ID: 29748135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
    Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation of KRAS in colorectal adenocarcinoma in Greenland.
    Mousavi N; Truelsen SLB; Bernth-Andersen S; Koch A; Heegaard S
    APMIS; 2022 Aug; 130(8):493-497. PubMed ID: 35655437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS
    Charitou T; Srihari S; Lynn MA; Jarboui MA; Fasterius E; Moldovan M; Shirasawa S; Tsunoda T; Ueffing M; Xie J; Xin J; Wang X; Proud CG; Boldt K; Al-Khalili Szigyarto C; Kolch W; Lynn DJ
    Br J Cancer; 2019 Jul; 121(1):37-50. PubMed ID: 31133691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.